Literature DB >> 34930468

Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19.

Yumi Mitsuyama1, Kazuma Yamakawa2, Katsuhide Kayano3, Miho Maruyama1, Takeshi Wada4, Satoshi Fujimi1.   

Abstract

We evaluated the peripheral blood immune responses of lymphocytes in severe Coronavirus disease 2019 (COVID-19) patients in different stages of recovery using single-cell mass cytometry. The patients with prolonged hospitalization did not show recovery of B lymphocyte counts and CD4-positive T lymphocyte counts but did show abundant CD8-positive T lymphocytes. CD4 and CD8 T cells expressing high levels of T-bet and Granzyme B were more abundant in post-recovery patients. This study showed that cytotoxic Th1 and CD8 T cells are recruited to the peripheral blood long after recovery from COVID-19.
© 2021. The Author(s).

Entities:  

Keywords:  COVID-19; Cytotoxic T lymphocytes; Granzyme B; Post-recovery; Single-cell mass cytometry; T-bet

Year:  2021        PMID: 34930468      PMCID: PMC8685802          DOI: 10.1186/s40560-021-00591-3

Source DB:  PubMed          Journal:  J Intensive Care        ISSN: 2052-0492


Dear Editor,

The pandemic of coronavirus disease 2019 (COVID-19) is a global public health emergency. Several studies have reported a complex network of peripheral blood immune responses in patients with COVID-19 [1]. However, very little is known about immune cell alterations in critically ill patients who have recovered from COVID-19. We profiled the characteristic peripheral cellular profiles of patients with COVID-19 using single-cell mass cytometry (cytometry by time-of-flight: CyTOF). Peripheral blood mononuclear cells (PBMCs) of six patients who recovered from severe COVID-19, three of whom were discharged (recovered patients: RP) and three who required prolonged hospitalization (hospitalized patients: HP) at the time of blood sampling, were compared with those of healthy donors (HD) (Table 1). Patients’ blood samples were collected about 3 months after admission.
Table 1

Patient characteristics

Hospitalized patientsbRecovered patientsHealthy donors
Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Donor 1Donor 2Donor 3Donor 4
Age, years75857367576265627170
SexFemaleMaleMaleMaleMaleFemaleFemaleFemaleMaleMale
Body mass index, kg/m220.522.720.924.52329.118.718.621.426.9
Past medical historyNoneHTNoneDMNoneNone
Clinical features at admission
Severity of ARDSaModerateSevereSevereModerateSevereSevere
APACHE II score18172010916
Disease course
ECMO −  −  −  −  +  + 
Tracheostomy +  +  +  +  −  − 
Length of stay in ICU, days372945271718
Days of mechanical ventilation, days423745341617
Length of stay in hospital, days156141187923167
DischargeNursing homeHomeHomeHomeHomeHome
Days from hospitalization to specimen100103981059587

ARDS acute diffuse respiratory syndrome, APACHE acute physiology and chronic health evaluation, ECMO extracorporeal membranous oxygenation, ICU intensive care unit, DM diabetes mellitus, HT hypertension

aSevere: 100 ≤ PaO2/FiO2, moderate: 100 < PaO2/FiO2 ≤ 200 (on positive end-expiratory pressure of 5 cmH2O)

bPatients who were hospitalized at the time of blood sample collection

Patient characteristics ARDS acute diffuse respiratory syndrome, APACHE acute physiology and chronic health evaluation, ECMO extracorporeal membranous oxygenation, ICU intensive care unit, DM diabetes mellitus, HT hypertension aSevere: 100 ≤ PaO2/FiO2, moderate: 100 < PaO2/FiO2 ≤ 200 (on positive end-expiratory pressure of 5 cmH2O) bPatients who were hospitalized at the time of blood sample collection A 43-marker antibody panel was used for CyTOF staining of PBMCs, which were analyzed on a Helios mass cytometer (Fluidigm Sciences Inc.). We identified seven cell subsets and visualized the changes in the cell populations of all samples on a t-distributed Stochastic Neighbor Embedding (t-SNE) map (Fig. 1A). For comparison of the three groups, data were concatenated within a group and the cell distribution was visualized on a t-SNE map (Fig. 1B). The contour density of B lymphocytes was lower in the HP group than that in the HD group, whereas that in the RP group had recovered to the same level as that in the HD group. CD4-positive T lymphocytes were fewer in the HP group, followed by the RP group, whereas CD8-positive T lymphocytes were more abundant in the RP and HP groups versus HD group. Natural killer (NK) cells were more abundant in the HP group, followed by the HD group, and were less frequent in the RP group. The frequency of protein expression inside and outside the cells of all samples is shown in the histogram (Fig. 2A). The data for each group were concatenated (Fig. 2B). CD4 T cells showing high expression of T-bet and Granzyme B were more abundant in the HP group, followed by the RP group. The number of CD8 T cells highly expressing T-bet and Granzyme B was also higher in the HP and RP groups (Fig. 2C).
Fig. 1

Characterization of peripheral blood mononuclear cells (PBMCs) in patients with COVID-19 and healthy donors. A The PBMC samples of all patients and the healthy donors were merged, and cell populations defined by the manual gating strategy were projected onto a t-SNE map and assigned specific colors. B Patient data within each group were concatenated by group, and CyTOF staining data for the three groups from CD45 + cells were analyzed by t-SNE and plotted as density contour plots. B cells B lymphocytes, CD4 T cells CD4 T lymphocytes, CD8 T cells CD8 T lymphocytes, D donor, HD healthy donors, HP hospitalized patients, MAIT mucosal-associated invariant T cells, NK natural killer cells, NKT natural killer T cells, HP hospitalized patient, RP recovered patient, HD healthy donor,  t-SNE t-distributed Stochastic Neighbor Embedding

Fig. 2

Expression of T-bet and Granzyme B on CD4 and CD8 T cells in patients with COVID-19 and healthy donors. A Histograms showing relative changes in expression intensities of the indicated markers on CD4 and CD8 T cells from the PBMCs of the patients and healthy donors. The color bar legend indicates differences in marker expression levels: yellow (increased) or black (decreased). B t-SNE projections of CD4 and CD8 T cells from the HP, RP and HD groups generated by concatenating patient data within each group for the indicated cell markers. C Violin plots showing the percentage of cells expressing the indicated markers in the three groups. The plots show the distribution of sample values. CD4 T cells CD4 T lymphocytes, CD8 T cells CD8 T lymphocytes, Grz B granzyme B, HD healthy donor, HP hospitalized patient, PMBCs peripheral blood mononuclear cells, RP recovered patient, tSNE t-distributed Stochastic Neighbor Embedding

Characterization of peripheral blood mononuclear cells (PBMCs) in patients with COVID-19 and healthy donors. A The PBMC samples of all patients and the healthy donors were merged, and cell populations defined by the manual gating strategy were projected onto a t-SNE map and assigned specific colors. B Patient data within each group were concatenated by group, and CyTOF staining data for the three groups from CD45 + cells were analyzed by t-SNE and plotted as density contour plots. B cells B lymphocytes, CD4 T cells CD4 T lymphocytes, CD8 T cells CD8 T lymphocytes, D donor, HD healthy donors, HP hospitalized patients, MAIT mucosal-associated invariant T cells, NK natural killer cells, NKT natural killer T cells, HP hospitalized patient, RP recovered patient, HD healthy donor,  t-SNE t-distributed Stochastic Neighbor Embedding Expression of T-bet and Granzyme B on CD4 and CD8 T cells in patients with COVID-19 and healthy donors. A Histograms showing relative changes in expression intensities of the indicated markers on CD4 and CD8 T cells from the PBMCs of the patients and healthy donors. The color bar legend indicates differences in marker expression levels: yellow (increased) or black (decreased). B t-SNE projections of CD4 and CD8 T cells from the HP, RP and HD groups generated by concatenating patient data within each group for the indicated cell markers. C Violin plots showing the percentage of cells expressing the indicated markers in the three groups. The plots show the distribution of sample values. CD4 T cells CD4 T lymphocytes, CD8 T cells CD8 T lymphocytes, Grz B granzyme B, HD healthy donor, HP hospitalized patient, PMBCs peripheral blood mononuclear cells, RP recovered patient, tSNE t-distributed Stochastic Neighbor Embedding We have shown the peripheral blood immune responses of lymphocytes and NK cells in severe COVID-19 patients in different stages of recovery. It has been reported that especially regarding B lymphocyte counts, lymphopenia of patients with acute-phase COVID-19 recovers after polymerase chain reaction tests become negative [2]. Our results suggest that long-term recovery of B lymphocytes might be related to the severity of illness and the current stage of recovery. The NK cell population is reported to be greatly altered in patients with acute COVID-19, with an expansion of the cytokine-producing NK cells and a decrease in the cytolytic NK cells responsible for innate immunity [3]. Although cytolytic NK cells recovered with improvement of the disease, the frequency of cytokine-producing NK cells remained elevated in severe COVID-19. Elevated cytokine-producing NK cells may lead to impaired NK cell cytotoxicity and decreased regulation of cellular and humoral adaptive immune responses [4]. T-bet is the master transcription factor of CD4 T helper type 1 (Th1) cells and plays a major part in protective immunity in cooperation with CD4, CD8 T cells and natural killer T (NKT) cells [5]. Granzyme B is mainly expressed on activated memory CD8 and memory CD4 T cells, NK cells and NKT cells during infection and inflammation, and has important roles in promoting removal of virus-infected cells by cytotoxic T cells and in suppressing the host immune response [6]. Therefore, the high expression of T-bet and Granzyme B in CD4 and CD8 T cells indicates increased cytotoxicity of lymphocytes. Previous reports showed that cytotoxicity is enhanced in CD4 and CD8 T cells in the acute phase of severe COVID-19, and the elevation in cytotoxic CD8 T cell counts persists after recovery [7, 8]. The present study also revealed that the persistence of T cells highly expressing T-bet and Granzyme B in the recovered COVID-19 patients might indicate prolonged suppression of the immune response and an unrecovered inflammatory process. Comparing the RP and HP groups, although recovery of B lymphocytes was restored in the RP group, the recruitment of cytotoxic T cells to the peripheral blood persisted in both post-COVID-19 groups. This may suggest that the activation of cellular immunity is more prolonged than that of humoral immunity in COVID-19, depending on the severity of the illness and the stage of recovery. These results suggest that restoration of immune homeostasis after COVID-19 may require a long time and that complications, such as secondary infections during the recovery process need to be addressed. Thus, the prolonged cytotoxicity of lymphocytes after recovery from COVID-19 may have implications for elucidation of the long-term changes in immune responses after COVID-19.
  8 in total

Review 1.  Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B.

Authors:  Inna S Afonina; Sean P Cullen; Seamus J Martin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  The evolving role of T-bet in resistance to infection.

Authors:  Gretchen Harms Pritchard; Ross M Kedl; Christopher A Hunter
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

3.  Single-cell multi-omics analysis of the immune response in COVID-19.

Authors:  Emily Stephenson; Gary Reynolds; Rachel A Botting; Fernando J Calero-Nieto; Michael D Morgan; Zewen Kelvin Tuong; Karsten Bach; Waradon Sungnak; Kaylee B Worlock; Masahiro Yoshida; Natsuhiko Kumasaka; Katarzyna Kania; Justin Engelbert; Bayanne Olabi; Jarmila Stremenova Spegarova; Nicola K Wilson; Nicole Mende; Laura Jardine; Louis C S Gardner; Issac Goh; Dave Horsfall; Jim McGrath; Simone Webb; Michael W Mather; Rik G H Lindeboom; Emma Dann; Ni Huang; Krzysztof Polanski; Elena Prigmore; Florian Gothe; Jonathan Scott; Rebecca P Payne; Kenneth F Baker; Aidan T Hanrath; Ina C D Schim van der Loeff; Andrew S Barr; Amada Sanchez-Gonzalez; Laura Bergamaschi; Federica Mescia; Josephine L Barnes; Eliz Kilich; Angus de Wilton; Anita Saigal; Aarash Saleh; Sam M Janes; Claire M Smith; Nusayhah Gopee; Caroline Wilson; Paul Coupland; Jonathan M Coxhead; Vladimir Yu Kiselev; Stijn van Dongen; Jaume Bacardit; Hamish W King; Anthony J Rostron; A John Simpson; Sophie Hambleton; Elisa Laurenti; Paul A Lyons; Kerstin B Meyer; Marko Z Nikolić; Christopher J A Duncan; Kenneth G C Smith; Sarah A Teichmann; Menna R Clatworthy; John C Marioni; Berthold Göttgens; Muzlifah Haniffa
Journal:  Nat Med       Date:  2021-04-20       Impact factor: 53.440

4.  Comprehensive mapping of immune perturbations associated with severe COVID-19.

Authors:  Leticia Kuri-Cervantes; M Betina Pampena; Wenzhao Meng; Aaron M Rosenfeld; Caroline A G Ittner; Ariel R Weisman; Roseline S Agyekum; Divij Mathew; Amy E Baxter; Laura A Vella; Oliva Kuthuru; Sokratis A Apostolidis; Luanne Bershaw; Jeanette Dougherty; Allison R Greenplate; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sigrid Gouma; Madison E Weirick; Claudia P Arevalo; Marcus J Bolton; Eileen C Goodwin; Elizabeth M Anderson; Scott E Hensley; Tiffanie K Jones; Nilam S Mangalmurti; Eline T Luning Prak; E John Wherry; Nuala J Meyer; Michael R Betts
Journal:  Sci Immunol       Date:  2020-07-15

5.  Alterations in T and B cell function persist in convalescent COVID-19 patients.

Authors:  Halima A Shuwa; Tovah N Shaw; Sean B Knight; Kelly Wemyss; Flora A McClure; Laurence Pearmain; Ian Prise; Christopher Jagger; David J Morgan; Saba Khan; Oliver Brand; Elizabeth R Mann; Andrew Ustianowski; Nawar Diar Bakerly; Paul Dark; Christopher E Brightling; Seema Brij; Timothy Felton; Angela Simpson; John R Grainger; Tracy Hussell; Joanne E Konkel; Madhvi Menon
Journal:  Med (N Y)       Date:  2021-03-31

Review 6.  Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.

Authors:  Marisa Market; Leonard Angka; Andre B Martel; Donald Bastin; Oladunni Olanubi; Gayashan Tennakoon; Dominique M Boucher; Juliana Ng; Michele Ardolino; Rebecca C Auer
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

7.  Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19.

Authors:  Benjamin J Meckiff; Ciro Ramírez-Suástegui; Vicente Fajardo; Serena J Chee; Anthony Kusnadi; Hayley Simon; Simon Eschweiler; Alba Grifoni; Emanuela Pelosi; Daniela Weiskopf; Alessandro Sette; Ferhat Ay; Grégory Seumois; Christian H Ottensmeier; Pandurangan Vijayanand
Journal:  Cell       Date:  2020-10-05       Impact factor: 41.582

8.  Abnormality in the NK-cell population is prolonged in severe COVID-19 patients.

Authors:  Galam Leem; Shinhye Cheon; Hoyoung Lee; Seong Jin Choi; Seongju Jeong; Eui-Soon Kim; Hye Won Jeong; Hyeongseok Jeong; Su-Hyung Park; Yeon-Sook Kim; Eui-Cheol Shin
Journal:  J Allergy Clin Immunol       Date:  2021-07-31       Impact factor: 10.793

  8 in total
  2 in total

1.  Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection.

Authors:  Milena Wiech; Piotr Chroscicki; Julian Swatler; Dawid Stepnik; Sara De Biasi; Michal Hampel; Marta Brewinska-Olchowik; Anna Maliszewska; Katarzyna Sklinda; Marek Durlik; Waldemar Wierzba; Andrea Cossarizza; Katarzyna Piwocka
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 2.  Update on Extracellular Vesicle-Based Vaccines and Therapeutics to Combat COVID-19.

Authors:  Tamanna Mustajab; Moriasi Sheba Kwamboka; Da Ae Choi; Dae Wook Kang; Junho Kim; Kyu Ri Han; Yujin Han; Sorim Lee; Dajung Song; Yong-Joon Chwae
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.